OrbusNeich Medical Group Holdings Limited

OrbusNeich Medical Group Holdings Limited

Q8T · F · Healthcare / Medical Instruments & Supplies

0.364EUR+0.00 (+0.55%)

Price History

Full chart

Market Stats

Previous Close0.362
Open0.364
Day Range0.364 – 0.364
52-Week Range0.2767 – 0.4594
Volume0
Market Cap302.96M
P/E (TTM)7.36
Forward P/E11.85
EPS0.05
Dividend Yield4.84%
Beta-0.63
50-Day Avg0.3602
200-Day Avg0.3644

About

OrbusNeich Medical Group Holdings Limited, an investment holding company, engages in the manufacture, trading, sale, and marketing of medical devices/instruments for the treatment of coronary and peripheral vascular diseases. The company offers semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, drug-coated balloons and stents for lesion therapy, non-compliant balloons for post-dilatation, and specialty catheters, as well as microcatheters, guide catheter extension, dual therapy, and drug eluting stents. Its product portfolio covers various treatment processes in percutaneous coronary intervention and percutaneous transluminal angioplasty procedures. It operates in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People's Republic of China, the United States, and internationally. The company was founded in 2001 and is headquartered in Sha Tin, Hong Kong. OrbusNeich Medical Group Holdings Limited is a subsidiary of Harmony Tree Limited.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. David Chien
  • Employees1.53K
  • HeadquartersBuilding 20E, Sha Tin, Hong Kong, Germany
  • Websitehttps://orbusneich.com

Leadership

  • Mr. David ChienChairman of the Board & Co-CEO · b. 1965
  • Ms. Kwai Ching LauCo-CEO & Executive Director · b. 1975
  • Mr. Wing Shing ChenCOO & Executive Director · b. 1982
  • Ms. Man Ying ChanCFO & Company Secretary · b. 1975
  • Mr. Alain Djamel KhairChief Commercial Officer · b. 1970

Financials

Income Statement

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue116.46M136.82M153.87M164.10M180.45M
Growth (%)-+17.48%+12.45%+6.65%+9.97%
Cost of Revenue35.29M44.37M47.37M49.63M58.02M
Gross Profit81.17M92.46M106.50M114.47M122.43M
Gross Margin69.70%67.57%69.22%69.76%67.85%
Operating Expense60.82M68.33M67.09M79.31M82.48M
Operating Income20.35M24.13M39.40M35.16M39.95M
Operating Margin17.47%17.64%25.61%21.42%22.14%
EBITDA-27.14M53.97M47.92M53.47M
EBITDA Margin-19.83%35.07%29.21%29.63%
Net Income-4.44M18.49M45.07M39.72M41.90M
Net Income Margin-3.82%13.51%29.29%24.20%23.22%
R&D12.15M14.11M14.38M17.05M15.73M
R&D as % of Total Revenue10.43%10.31%9.35%10.39%8.72%
Interest Expense5.61M1.46M134.00K218.00K168.00K
Interest Expense % of Total Revenue4.81%1.07%0.09%0.13%0.09%

Balance Sheet

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets268.53M351.06M410.14M431.01M452.91M
Total Liabilities85.42M28.49M40.73M36.63M38.71M
Total Equity183.11M322.57M368.40M393.31M413.05M
Cash175.89M229.15M255.78M248.59M218.70M

Cash Flow

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow20.50M23.43M23.03M13.11M19.53M
Capital Expenditure2.14M3.33M7.48M11.27M18.38M
Free Cash Flow18.36M20.10M15.55M1.84M1.15M
Dividends Paid---10.62M26.55M
FCF to OCF89.56%85.77%67.53%14.05%5.88%
Dividend Paid to FCF---575.96%2310.62%

Key Statistics & Ratios

Market Cap302.96M
Enterprise Value176.62M
Trailing P/E7.36
Forward P/E11.85
PEG Ratio0.86
Price / Sales1.55
Price / Book0.78
EPS0.05
Book Value0.4485
Revenue (TTM)195.61M
Gross Profit (TTM)134.19M
EBITDA49.14M
Profit Margin22.33%
Operating Margin21.84%
Return on Equity10.57%
Return on Assets6.24%
Shares Outstanding823.25M
Shares Float225.32M
Beta-0.63
Dividend Yield4.84%
Dividend Rate0.02
Payout Ratio28.93%

Dividends

20262×
0.01Sep 18, 20260.01Jun 10, 2026
20252×
0.02Sep 18, 20250.01May 29, 2025
20241×
0.01Jun 11, 2024